Boston Scientific Corporation (BSX) posted strong Q2 results, with adjusted EPS of 75 cents, a 20.9% increase from last year. Revenues rose 22.8% to $5.06 billion, driven by Cardiovascular growth and strong U.S. performance. BSX raised its 2025 sales growth forecast to 18-19% and EPS guidance to $2.95-$2.99. The company’s Q2 revenues by region showed growth in the United States, Europe, Asia Pacific, and Latin America. The company’s MedSurg and Cardiovascular segments both saw revenue increases. BSX’s gross margin contracted in Q2, and the company updated its 2025 outlook with positive guidance for the year and Q3.

Overall, Boston Scientific’s performance in Q2 exceeded expectations, reflecting strong product portfolio and global team engagement. The company achieved milestones in various segments and received FDA approval for its FARAPULSE PFA System expansion. BSX’s raised sales and EPS guidance for 2025 signal optimism, despite margin contraction in Q2. The company currently holds a Zacks Rank #2. Other top-ranked stocks in the medical space include Cencora (COR), Veeva Systems (VEEV), and Resmed (RMD). COR, VEEV, and RMD have all shown strong financial performance and growth potential.

Read more at Zacks Investment Research: Boston Scientific Beats on Q2 Earnings, Raises 2025 View, Stock Up – July 23, 2025